Shin Yu-yeol, the eldest son of Shin Dong-bin, Chairman of Lotte Group, will attend the JP Morgan Healthcare Conference held in San Francisco, USA, from the 13th to the 16th of this month (local time).
On the opening day of CES 2025, the world's largest consumer electronics and information technology (IT) exhibition, on the 7th (local time), Shin Yu-yeol, Vice President and Head of Future Growth at Lotte Holdings, visited the Lotte Innovate Exhibition Hall in the North Hall of the Las Vegas Convention Center in Nevada, USA. Photo by Yonhap News
According to business circles on the 13th, Vice President Shin will visit the JP Morgan Healthcare Conference site to observe the latest trends and technologies in the global bio industry and seek new business opportunities. He concurrently serves as the Head of Global Strategy at Lotte Biologics along with his role as Head of Future Growth at Lotte Holdings.
Earlier, on the 7th of this month (local time), Vice President Shin visited the world's largest home appliances and IT exhibition, 'CES 2025.' He visited the Lotte Innovate booth located in the North Hall of the Las Vegas Convention Center, experiencing the ultra-realistic metaverse platform Caliverse and viewing exhibits such as the electric vehicle charger EVSIS.
After returning from the US, Vice President Shin attended the 2025 first half VCM (Value Creation Meeting, formerly the Presidents' Meeting) held at Lotte Hotel World in Jamsil, Seoul, on the afternoon of the 9th, and then departed again to attend the JP Morgan Conference.
Lotte Group has designated Lotte Biologics' Contract Development and Manufacturing Organization (CDMO) business as one of its new growth businesses and is focusing investments accordingly. Lotte Holdings owns 80% of Lotte Biologics' shares, while Japan's Lotte Holdings holds 20%. Established in June 2022, Lotte Biologics aims to become a global top 10 CDMO company by 2030 through a two-track strategy of 'acquisitions' and 'new construction.'
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

